BPMC - ブル―プリント・メディシンズ (Blueprint Medicines Corporation) ブル―プリント・メディシンズ

 BPMCのチャート


 BPMCの企業情報

symbol BPMC
会社名 Blueprint Medicines Corp (ブル―プリント・メディシンズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ブループリント・メディシンズ(Blueprint Medicines Corporation)はバイオ医薬品会社である。同社は、異常なキナーゼ活性化によって遺伝的に定義された疾患患者を中心とする。同社は適切な治療オプションがない患者に臨床的応答を提供する薬剤候補を作ることに焦点を当てる。同社は癌と遺伝病における小分子薬物パイプラインを開発した。薬剤候補のBLU-285は、エクソン17突然変異を含むKIT、及びD842V突然変異を含むPDGFRaを対象とする。これらの突然変異は、胃腸間質腫瘍(GIST)および全身性肥満細胞症(SM)を含む癌および増殖性障害の原因である受容体チロシンキナーゼを活性化する。薬物候補BLU-554は、肝細胞癌の一般的なタイプである肝細胞癌(HCC)を有する患者の定義されたサブセットにおいて活性化されるキナーゼであるFGFR4を対象とする。同社は突然変異または転座によって活性化された受容体チロシンキナーゼであるRETを対象とする薬剤候補のBLU-667の開発に従事している。   ブル―プリント・メディシンズは米国のバイオ医薬品会社。がん分子標的治療薬やキナ―ゼ阻害剤の開発を行う。異常なキナ―ゼ活性化によって発症するゲノム的に定義された疾患向け治療薬の開発に従事する。同社の「BLU-285」は、全身性肥満細胞症で胃腸管の消化管間質腫瘍や骨髄増殖性障害を有する患者向けに開発された。本社はマサチュ―セッツ州ケンブリッジ。  
本社所在地 45 Sidney Street Suite 200 Cambridge MA 02139 USA
代表者氏名 Daniel S. Lynch ダニエルS.リンチ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-374-7580
設立年月日 39722
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 149人
url www.blueprintmedicines.com
nasdaq_url https://www.nasdaq.com/symbol/bpmc
adr_tso
EBITDA EBITDA(百万ドル) -174.38100
終値(lastsale) 69.43
時価総額(marketcap) 3047125232.76
時価総額 時価総額(百万ドル) 311.137
売上高 売上高(百万ドル) 52.08900
企業価値(EV) 企業価値(EV)(百万ドル) 2398.373
当期純利益 当期純利益(百万ドル) -170.32700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Blueprint Medicines Corp revenues increased from $11.7M to $42.4M. Net loss increased 36% to $83.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other Research and development increase of 71% to $101.2M (expense) Other General and administrative increase of 63% to $16.2M (expense).

 BPMCのテクニカル分析


 BPMCのニュース

   Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis  2020/12/07 13:00:00 PR Newswire
CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from six oral and poster presentations highlighted at the virtual…
   The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod  2020/12/02 12:35:27 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 1) AbbVie Inc (NYSE: ABBV ) Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT ) argenx SE – ADR (NASDAQ: ARGX ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Auris Medical Holding Ltd (NASDAQ: EARS ) (announced positive efficacy data from lab testing of AM-301 against airborne pathogens and allergens, including SARS-CoV-2) Beam Therapeutics Inc (NASDAQ: BEAM ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BioNTech SE – ADR (NASDAQ: BNTX ) BioTelemetry Inc (NASDAQ: BEAT ) Blueprint Medicines Corp (NASDAQ: BPMC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (announced FDA acceptance of NDA for infigratinib for individuals with cancer of the bile ducts) Cardiff Oncology Inc (NASDAQ: CRDF ) Cellectis SA (NASDAQ: CLLS ) Cerevel Therapeutics Holdings Inc (NASDAQ: CERE ) Codiak BioSciences Inc (NASDAQ: CDAK ) strong>Crispr Therapeutics AG (NASDAQ: CRSP ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Foghorn Therapeutics Inc.
   Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition  2020/11/23 13:00:00 PR Newswire
CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to report data presentations highlighting the medical needs in…
   Earnings Scheduled For October 29, 2020  2020/10/29 08:08:21 Benzinga
Companies Reporting Before The Bell • PG&E (NYSE: PCG ) is likely to report quarterly earnings at $0.27 per share on revenue of $4.72 billion. • Silicom (NASDAQ: SILC ) is estimated to report quarterly earnings at $0.35 per share on revenue of $26.68 million. • Ambev (NYSE: ABEV ) is expected to report quarterly earnings at $0.02 per share on revenue of $2.28 billion. • Ares Commercial Real (NYSE: ACRE ) is estimated to report quarterly earnings at $0.24 per share on revenue of $17.15 million. • Alliance Data Systems (NYSE: ADS ) is expected to report quarterly earnings at $2.20 per share on revenue of $1.01 billion. • Agenus (NASDAQ: AGEN ) is expected to report quarterly loss at $0.26 per share on revenue of $14.00 million. • Alexion Pharmaceuticals (NASDAQ: ALXN ) is projected to report quarterly earnings at $2.58 per share on revenue of $1.42 billion. • AMETEK (NYSE: AME ) is estimated to report quarterly earnings at $0.93 per share on revenue of $1.11 billion. • Amerant Bancorp (NASDAQ: AMTB ) is projected to report quarterly earnings at $0.
   Analysts Expect Blueprint Medicines Corp (NASDAQ:BPMC) Will Post Quarterly Sales of $565.91 Million  2020/10/24 13:28:56 The Olympia Report
Equities research analysts expect that Blueprint Medicines Corp (NASDAQ:BPMC) will announce sales of $565.91 million for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Blueprint Medicines’ earnings, with the lowest sales estimate coming in at $57.30 million and the highest estimate coming in at $781.20 million. Blueprint Medicines posted sales […]
   Earnings Scheduled For October 29, 2020  2020/10/29 08:08:21 Benzinga
Companies Reporting Before The Bell • PG&E (NYSE: PCG ) is likely to report quarterly earnings at $0.27 per share on revenue of $4.72 billion. • Silicom (NASDAQ: SILC ) is estimated to report quarterly earnings at $0.35 per share on revenue of $26.68 million. • Ambev (NYSE: ABEV ) is expected to report quarterly earnings at $0.02 per share on revenue of $2.28 billion. • Ares Commercial Real (NYSE: ACRE ) is estimated to report quarterly earnings at $0.24 per share on revenue of $17.15 million. • Alliance Data Systems (NYSE: ADS ) is expected to report quarterly earnings at $2.20 per share on revenue of $1.01 billion. • Agenus (NASDAQ: AGEN ) is expected to report quarterly loss at $0.26 per share on revenue of $14.00 million. • Alexion Pharmaceuticals (NASDAQ: ALXN ) is projected to report quarterly earnings at $2.58 per share on revenue of $1.42 billion. • AMETEK (NYSE: AME ) is estimated to report quarterly earnings at $0.93 per share on revenue of $1.11 billion. • Amerant Bancorp (NASDAQ: AMTB ) is projected to report quarterly earnings at $0.
   Analysts Expect Blueprint Medicines Corp (NASDAQ:BPMC) Will Post Quarterly Sales of $565.91 Million  2020/10/24 13:28:56 The Olympia Report
Equities research analysts expect that Blueprint Medicines Corp (NASDAQ:BPMC) will announce sales of $565.91 million for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Blueprint Medicines’ earnings, with the lowest sales estimate coming in at $57.30 million and the highest estimate coming in at $781.20 million. Blueprint Medicines posted sales […]
   Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020  2020/10/22 12:00:00 PR Newswire
CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ET…
   Kate Haviland Sells 13,334 Shares of Blueprint Medicines Corp (NASDAQ:BPMC) Stock  2020/10/22 01:24:54 Daily Political
Blueprint Medicines Corp (NASDAQ:BPMC) COO Kate Haviland sold 13,334 shares of the stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $101.23, for a total value of $1,349,800.82. Following the transaction, the chief operating officer now directly owns 56,172 shares of the company’s stock, valued […]
   The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings  2020/10/21 12:04:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )( announced a reverse merger with Cytocom) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Insmed Incorporated (NASDAQ: INSM ) Laboratory Corp. of America Holdings (NYSE: LH ) Pacific Biosciences of California Inc (NASDAQ: PACB ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Alector Inc (NASDAQ: ALEC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Baudax Bio Inc (NASDAQ: BXRX ) (issued a corporate update) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq on Oct. 14) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ProQR Therapeutics NV (NASDAQ: PRQR ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA ) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) plans …
   Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO™ (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Cancer  2020/09/20 12:25:00 PR Newswire
CAMBRIDGE, Mass., Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced results from the ongoing ARROW clinical trial showing durable…
   Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020  2020/09/17 12:00:00 PR Newswire
CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced preclinical proof-of-concept data for BLU-945, an investigational…
   Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference  2020/09/09 20:01:00 PR Newswire
CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Jeff Albers, Blueprint Medicines' Chief Executive Officer, will…
   Roche, Blueprint lung cancer drug wins FDA approval  2020/09/05 00:25:14 Channel NewsAsia
Roche Holding AG on Friday said a therapy it co-developed with Cambridge-based Blueprint Medicines Corp was approved by the U.S. health regulator …
   Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer  2020/09/04 23:00:00 PR Newswire
CAMBRIDGE, Mass., Sept. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ブル―プリント・メディシンズ BPMC Blueprint Medicines Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)